All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
2022-12-22T13:43:14.000Z

What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy?

Dec 22, 2022
Share:

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Veit L. Buecklein, Ludwig-Maximilians-Universitat, Munich, DE. We asked, What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Veit L. Buecklein, Ludwig-Maximilians-Universitat, Munich, DE. We asked, What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy?

Buecklein begins by discussing findings from a real-world analysis comparing progression-free survival, overall survival, response rates, toxicity, and non-relapse mortality in EU vs US patients with DLBCL after CAR T-cell therapy. Buecklein then outlines possible reasons for these differences, including the adverse risk-profiles of patients, availability of product types, and time between treatment and CAR T-cell infusion for different indications.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you